Jose L Perez-Calle
Overview
Explore the profile of Jose L Perez-Calle including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
94
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gonzalez-Munoza C, Calafat M, Gisbert J, Iglesias E, Minguez M, Sicilia B, et al.
Postgrad Med J
. 2024 Jun;
100(1189):836-844.
PMID: 38913019
Background And Aims: Familial inflammatory bowel disease (IBD) history is a controversial prognostic factor in IBD. We aimed to evaluate the impact of a familial history of IBD on the...
2.
Gomez-Labrador C, Ricart E, Iborra M, Iglesias E, Martin-Arranz M, De Castro L, et al.
Pharmaceutics
. 2024 May;
16(5).
PMID: 38794292
Markers that allow for the selection of tailored treatments for individual patients with inflammatory bowel diseases (IBD) are yet to be identified. Our aim was to describe trends in real-life...
3.
Echarri A, Perez-Calle J, Calvo M, Molina G, Sierra-Ausin M, Morete-Perez M, et al.
Telemed J E Health
. 2022 Dec;
29(10):1504-1513.
PMID: 36576850
nnnnnnnnn
4.
Calafat M, Manosa M, Ricart E, Nos P, Iglesias-Flores E, Vera I, et al.
J Crohns Colitis
. 2021 Dec;
16(6):946-953.
PMID: 34864947
Background And Aims: Immunomediated adverse events [IAEs] are the most frequently reported infliximab [IFX]-related adverse events. Combination therapy may reduce their incidence, although this strategy is not recommended in elderly...
5.
Martinez-Lozano H, Miranda-Bautista J, Gonzalez-Lama Y, Carpio D, Barreiro-de Acosta M, Perez-Calle J, et al.
Rev Esp Enferm Dig
. 2020 Nov;
113(3):170-178.
PMID: 33213166
Purpose: biosimilar infliximab (CTP-13) has been recently approved for the treatment of several immune-mediated inflammatory disorders, including inflammatory bowel disease (IBD). Comparative studies between this biosimilar and original infliximab in...
6.
Algaba A, Guerra I, Ricart E, Iglesias E, Manosa M, Gisbert J, et al.
Dig Dis Sci
. 2020 Jul;
66(6):2014-2023.
PMID: 32671587
Background: Patients with inflammatory bowel disease (IBD) may present extraintestinal manifestations (EIMs) that affect the joints, skin, eyes, and hepatobiliary area, among others. Aims: Our aim was to analyse the...
7.
Medrano L, Taxonera C, Gonzalez-Artacho C, Pascual V, Gomez-Garcia M, Barreiro-de Acosta M, et al.
Mediators Inflamm
. 2015 Sep;
2015:318207.
PMID: 26339133
Substantial proportion of Crohn's disease (CD) patients shows no response or a limited response to treatment with infliximab (IFX) and to identify biomarkers of response would be of great clinical...
8.
Marin-Jimenez I, Gisbert J, Perez-Calle J, Garcia-Sanchez V, Tabernero S, Garcia-Vicuna R, et al.
Gastroenterol Hepatol
. 2015 May;
38(10):569-74.
PMID: 25983283
Objective: To describe the 2-year incidence of new immune-mediated inflammatory diseases (spondylarthritis, uveitis, psoriasis) in the cohort of patients with inflammatory bowel disease (IBD) included in the AQUILES study. Materials...
9.
Sanchez-Tembleque M, Corella C, Perez-Calle J
World J Gastroenterol
. 2013 Mar;
19(9):1354-8.
PMID: 23538680
The patient with inflammatory bowel disease will be predisposed to numerous infections due their immune status. It is therefore important to understand the immune and serologic status at diagnosis and...
10.
Nunes T, Barreiro-de Acosta M, Nos P, Marin-Jimenez I, Bermejo F, Ceballos D, et al.
J Crohns Colitis
. 2010 Dec;
4(6):629-36.
PMID: 21122572
Background: Beclometasone dipropionate (BDP) is a relatively new topically acting oral steroid to treat mild to moderately active ulcerative colitis (UC). We estimate that 20,000 patients have received oral BDP...